Potent in vivo anti-tumor activity of isolated CD62L^low lymph node cells sensitized in vivo with tumor lysate-pulsed DC-based vaccines

References

• Chou T, Chang AE, Shu SY. Generation of therapeutic T lymphocytes from tumor-bearing mice by in vitro sensitization. Culture requirements and characterization of immunologic specificity. J Immunol 1988; 140: 2453–61
   PubMed Web of Science ®Google Scholar
• Shu S, Chou T, Rosenberg SA. In vitro differentiation of T-cells capable of mediating the regression of established syngeneic tumors in mice. Cancer Res 1987; 47: 1354–60
   PubMedGoogle Scholar
• Shu SY, Chou T, Rosenberg SA. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy. J Immunol 1987; 139: 295–304
   PubMed Web of Science ®Google Scholar
• Yoshizawa H, Chang AE, Shu S. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J Immunol 1991; 147: 729–37
   PubMed Web of Science ®Google Scholar
• Kagamu H, Touhalisky JE, Plautz GE, et al. Isolation based on l-selectin expression of immune effector T cells derived from tumor-draining lymph nodes. Cancer Res 1996; 56: 4338–42
   PubMedGoogle Scholar
• Kagamu H, Shu S. Purification of l-selectin(low) cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes. J Immunol 1998; 160: 3444
   PubMed Web of Science ®Google Scholar
• Peng L, Shu S, Krauss JC. Treatment of subcutaneous tumor with adoptively transferred T cells. Cell Immunol 1997; 178: 24
   PubMedGoogle Scholar
• Plautz GE, Touhalisky JE, Shu S. Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells. Cell Immunol 1997; 178: 101–7
   PubMedGoogle Scholar
• Plautz GE, Barnett GH, Miller DW, et al. Systemic T cell adoptive immunotherapy of malignant gliomas. J Neurosurg 1998; 89: 42–51
   PubMed Web of Science ®Google Scholar
• Plautz GE, Bukowski RM, Novick AC, et al. T-cell adoptive immunotherapy of metastatic renal cell carcinoma. Urology 1999; 54: 617–23
   PubMed Web of Science ®Google Scholar
• Chang AE, Sondak VK, Bishop DK, et al. Adoptive immunotherapy of cancer with activated lymph node cells primed in vivo with autologous tumor cells transduced with the GM-CSF gene. Hum Gene Ther 1996; 7: 773–92
   PubMedGoogle Scholar
• Chang AE, Aruga A, Cameron MJ, et al. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J Clin Oncol 1997; 15: 796–807
   PubMed Web of Science ®Google Scholar
• Fujita N, Kagamu H, Yoshizawa H, et al. CD40 ligand promotes priming of fully potent antitumor CD4(+) T cells in draining lymph nodes in the presence of apoptotic tumor cells. J Immunol 2001; 167: 5678–88
   PubMedGoogle Scholar
• Albert ML, Pearce SF, Francisco LM, et al. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 1998; 188: 1359–68
   PubMed Web of Science ®Google Scholar
• Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245–52
   PubMed Web of Science ®Google Scholar
• Rodriguez A, Regnault A, Kleijmeer M, et al. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol 1999; 1: 362–8
   PubMed Web of Science ®Google Scholar
• Heath WR, Carbone FR. Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol 2001; 19: 47–64
   PubMed Web of Science ®Google Scholar
• Subklewe M, Paludan C, Tsang ML, et al. Dendritic cells cross-present latency gene products from Epstein–Barr virus-transformed B cells and expand tumor-reactive CD8(+) killer T cells. J Exp Med 2001; 193: 405–412
   PubMed Web of Science ®Google Scholar
• Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996; 184: 465–72
   PubMed Web of Science ®Google Scholar
• Boczkowski D, Nair SK, Nam JH, et al. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res 2000; 60: 1028–34
   PubMed Web of Science ®Google Scholar
• Celluzzi CM, Mayordomo JI, Storkus WJ, et al. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 1996; 183: 283–7
   PubMed Web of Science ®Google Scholar
• Fields RC, Shimizu K, Mule JJ. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA 1998; 95: 9482–7
   PubMed Web of Science ®Google Scholar
• Paglia P, Chiodoni C, Rodolfo M, Colombo MP. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 1996; 183: 317–22
   PubMed Web of Science ®Google Scholar
• Shimizu K, Fields RC, Giedlin M, Mule JJ. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proc Natl Acad Sci USA 1999; 96: 2268–73
   PubMed Web of Science ®Google Scholar
• Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999; 163: 5211–8
   PubMed Web of Science ®Google Scholar
• Shimizu K, Thomas EK, Giedlin M, Mule JJ. Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein. Cancer Res 2001; 61: 2618–24
   PubMed Web of Science ®Google Scholar
• Almand B, Clark JI, Nikitina E, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001; 166: 678–89
   PubMed Web of Science ®Google Scholar
• Staveley-O'Carroll K, Sotomayor E, Montgomery J, et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci USA 1998; 95: 1178–83
   PubMed Web of Science ®Google Scholar
• Weber JS, Mule JJ. How much help does a vaccine-induced T-cell response need?. J Clin Invest 2001; 107: 553–4
   PubMedGoogle Scholar
• Tanigawa K, Takeshita N, Eickhoff GA, et al. Antitumor reactivity of lymph node cells primed in vivo with dendritic cell-based vaccines. J Immunother 2001; 24: 493–501
   PubMedGoogle Scholar
• Lanzavecchia A, Sallusto F. Regulation of T cell immunity by dendritic cells. Cell 2001; 106: 263–6
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Steinman RM, Krasovsky J, et al. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001; 193: 233–8
   PubMed Web of Science ®Google Scholar
• Jonuleit H, Schmitt E, Schuler G, et al. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000; 192: 1213–22
   PubMed Web of Science ®Google Scholar
• Schuurhuis DH, Laban S, Toes RE, et al. Immature dendritic cells acquire CD8(+) cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli. J Exp Med 2000; 192: 145–50
   PubMed Web of Science ®Google Scholar
• Sauter B, Albert ML, Francisco L, et al. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 2000; 191: 423–34
   PubMed Web of Science ®Google Scholar
• Barth RJ, Jr, Bock SN, Mule JJ, Rosenberg SA. Unique murine tumor-associated antigens identified by tumor infiltrating lymphocytes. J Immunol 1990; 144: 1531–7
   PubMed Web of Science ®Google Scholar
• Wang LX, Chen BG, Plautz GE. Adoptive immunotherapy of advanced tumors with CD62 l-selectin(low) tumor-sensitized T lymphocytes following ex vivo hyperexpansion. J Immunol 2002; 169: 3314–20
   PubMedGoogle Scholar
• Chen B, Shi Y, Smith JD, et al. The role of tumor necrosis factor alpha in modulating the quantity of peripheral blood-derived, cytokine-driven human dendritic cells and its role in enhancing the quality of dendritic cell function in presenting soluble antigens to CD4+ T cells in vitro. Blood 1998; 91: 4652–61
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Steinman RM, Sapp M, et al. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest 1999; 104: 173–80
   PubMed Web of Science ®Google Scholar
• Barth RJ, Jr, Mule JJ, Spiess PJ, Rosenberg SA. Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med 1991; 173: 647–58
   PubMed Web of Science ®Google Scholar
• Qin Z, Blankenstein T. CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 2000; 12: 677–86
   PubMed Web of Science ®Google Scholar
• Mukai S, Kjaergaard J, Shu S, Plautz GE. Infiltration of tumors by systemically transferred tumor-reactive T lymphocytes is required for antitumor efficacy. Cancer Res 1999; 59: 5245–9
   PubMed Web of Science ®Google Scholar
• Labeur MS, Roters B, Pers B, et al. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J Immunol 1999; 162: 168–75
   PubMed Web of Science ®Google Scholar
• Mule JJ. Tumor vaccine strategies that employ dendritic cells and tumor lysates: experimental and clinical studies. Immunol Invest 2000; 29: 127–9
   PubMedGoogle Scholar
• Banchereau J, Schuler-Thurner B, Palucka AK, Schuler G. Dendritic cells as vectors for therapy. Cell 2001; 106: 271–4
   PubMed Web of Science ®Google Scholar
• Pasche B. Role of transforming growth factor beta in cancer. J Cell Physiol 2001; 186: 153–68
   PubMed Web of Science ®Google Scholar
• Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 2001; 7: 1118–22
   PubMed Web of Science ®Google Scholar
• Shevach EM, McHugh RS, Piccirillo CA, Thornton AM. Control of T-cell activation by CD4+ CD25+ suppressor T cells. Immunol Rev 2001; 182: 58–67
   PubMed Web of Science ®Google Scholar
• Shevach EM. Certified professionals: CD4(+)CD25(+) suppressor T cells. J Exp Med 2001; 193: F41–6
   PubMed Web of Science ®Google Scholar
• Piccirillo CA, Shevach EM. Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 2001; 167: 1137–40
   PubMed Web of Science ®Google Scholar
• Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001; 61: 4766–72
   PubMed Web of Science ®Google Scholar
• Hawiger D, Inaba K, Dorsett Y, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001; 194: 769–79
   PubMed Web of Science ®Google Scholar
• Roncarolo MG, Levings MK, Traversari C. Differentiation of T regulatory cells by immature dendritic cells. J Exp Med 2001; 193: F5–9
   PubMed Web of Science ®Google Scholar
• Mosca PJ, Hobeika AC, Clay TM, et al. A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-gamma treatment. Blood 2000; 96: 3499–504
   PubMed Web of Science ®Google Scholar